|
|
|
News For PFE;BMY;NVS;LLY From The Last 14 Days Check below for free stories on PFE;BMY;NVS;LLY the last two weeks. |
|
|
| June 20, 2013 | | 08:11 EDT |  | PFE | Pfizer investors should participate in Zoetis spinoff, says BMO Capital
 Subscribe for More Information | | | June 19, 2013 | | 17:52 EDT |  | PFE | Pfizer announces final exchange ratio for Zoetis exchange offer
Subscribe for More Information | | | 16:01 EDT |  | PFE | Options Update; June 19, 2013
Subscribe for More Information | | | 15:17 EDT | | LLY | Eli Lilly issues alert for illegal scams
Eli Lilly and Company issued an alert about two illegal scams, purportedly using the name of the company and/or its subsidiary Elanco Animal Health, that are actively targeting the public through postal mail solicitations and job-seekers through online dialogue. Lilly and Elanco have no connection to any foreign lottery organizations and do not conduct the type of online recruiting described by the job-seeking victims of the scam. The activities described in these scams are completely fraudulent and are in no way affiliated with, or sponsored by, Eli Lilly and Company or its affiliates or subsidiaries. | | | 10:30 EDT |  | PFE | Pfizer management to meet with ISI Group
Subscribe for More Information | | | 07:41 EDT | | PFE | Pfizer holders should consider Zoetis exchange, says BMO Capital
BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis. | | | 05:43 EDT | | BMY | AstraZeneca, Bristol-Myers announce top line results of Phase 4 trial of Onglyza
Subscribe for More Information | | | June 18, 2013 | | 10:17 EDT | | LLY | Lilly puts active on FDA says investigating two deaths after Zyprexa injections
Subscribe for More Information | | | 10:12 EDT | | LLY | FDA investigating two deaths of patients taking Lilly's Zyprexa
The FDA said in a safety announcement on its website that it is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa. The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Risk Evaluation and Mitigation Strategy, the agency said. Both patients were found to have very high olanzapine blood levels after death. Eli Lilly is the maker of Zyprexa. | | | 09:38 EDT | | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM | | | | 07:22 EDT | | NVS | Citigroup to host a conference
Subscribe for More Information | | | June 17, 2013 | | 16:00 EDT | | PFE | Options Update; June 17, 2013
Subscribe for More Information | | | 11:34 EDT | | LLY | Eli Lilly: LIVALO 4mg has neutral effects on fasting serum glucose levels
Kowa Pharmaceuticals America and Eli Lilly and Company announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating the effect of LIVALO 4 mg compared with pravastatin 40 mg on changes in levels of blood glucose and glycated hemoglobin in HIV-infected adults with dyslipidemia. INTREPID was a Phase 4, multicenter, 12-week randomized superiority study followed by a 40-week safety extension study comparing the lipid-lowering effects of pitavastatin 4 mg and pravastatin 40 mg in adults with HIV infection and dyslipidemia. The results of this pre-specified safety analysis, presented yesterday at the Endocrine Society's 95th Annual Meeting & Expo in San Francisco, CA, showed neutral effects of pitavastatin 4 mg and pravastatin 40 mg on fasting serum glucose and HbA1c levels over 12 weeks. | | | 11:17 EDT | | LLY | Eli Lilly to host conference call
Subscribe for More Information | | | 08:36 EDT | | PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. | | | 07:28 EDT | | PFE, BMY, NVS | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | | | 07:25 EDT | | NVS | Leerink to host a conference
Subscribe for More Information | | | 06:06 EDT | | LLY | Transition Therapeutics announces exercise of TT-401 rights by Eli Lilly
Transition Therapeutics (TTHI) announced that Eli Lilly (LLY) has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. In conjunction with this assumption of rights, Transition will receive a $7M milestone payment. Lilly and Transition have amended their agreement to address future development of TT-401 and associated financial arrangements. Lilly will assume all costs and perform all future development and commercialization activities of TT-401. Transition will contribute payment of $14M to Lilly in three separate installments during the Phase 2 clinical study. If TT-401 is successfully commercialized, Transition will be eligible to receive approximately $240M in additional milestone payments. Transition will also be eligible to receive a double-digit royalty on sales of TT-401 products and a low single digit royalty on related compounds. | | | June 16, 2013 | | 14:09 EDT | | NVS | Jakafi improved overall survival in Phase III trial of patients with myelofibros
Incyte (INCY) announced results from two ongoing clinical trials of Jakafi, ruxolitinib, an oral JAK1 and JAK2 inhibitor that is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis, MF, that were presented at the 18th Congress of the European Hematology Associationm EHA, in Stockholm, Sweden. In a three-year follow-up analysis of the Phase III COMFORT-II study, treatment with Jakafi, which is marketed as Jakavi by Novartis (NVS) outside the United States, was associated with improved overall survival and sustained reductions in spleen size compared to best available therapy. In a separate exploratory analysis of bone marrow fibrosis data from an ongoing Phase I/II single-arm, open-label clinical trial, by 48 months of treatment, Jakafi stabilized or reversed fibrosis of the bone marrow in 56 percent and 22 percent, respectively, of patients with MF, a magnitude of an effect not seen historically with best available therapy. | | | June 14, 2013 | | 16:00 EDT | | PFE | Options Update; June 14, 2013
Subscribe for More Information | | | | 09:03 EDT | | BMY | Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions
AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. | | | 08:02 EDT | | BMY | Bristol-Myers, Simcere enter Orencia pact for China
Subscribe for More Information | | | 06:45 EDT | | PFE | Zoetis volatility elevated into Pfizer split-off
Subscribe for More Information | | | June 13, 2013 | | 16:45 EDT | | LLY | Eli Lilly terminates Phase II study for beta secretase inhibitor
Subscribe for More Information | | | 16:00 EDT | | PFE | Options Update; June 13, 2013
Subscribe for More Information | | | 14:36 EDT | | LLY | Lilly, Boehringer Ingelheim support ADA call for review of incretin therapies
Subscribe for More Information | | | 14:33 EDT | | LLY | Eli Lilly July volatility elevated into diabetes business update
Subscribe for More Information | | | 11:02 EDT | | BMY | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information | | | 07:32 EDT | | PFE | European League Against Rheumatism to host annual meeting
Subscribe for More Information | | | 06:05 EDT | | LLY | Eli Lilly, Incyte announce efficacy data of baricitinib Phase 2b JADA study
Subscribe for More Information | | | | June 12, 2013 | | 16:02 EDT | | PFE | Options Update; June 12, 2013
Subscribe for More Information | | | 13:31 EDT | | PFE | Mylan could be interested in generic assets split from Pfizer, Bloomberg says
| | | 13:15 EDT | | BMY | Bristol-Myers, AstraZeneca issue statement on review of some therapies
Subscribe for More Information | | | 08:28 EDT | | PFE | Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix
Subscribe for More Information | | | 08:02 EDT | | PFE | Pfizer wins $2.15B settlement from Teva and Sun for patent infringement
Subscribe for More Information | | | June 11, 2013 | | 18:09 EDT | | BMY | Orencia trial data shows efficacy rate comparable to Humira
Bristol-Myers announced the results of year two data from AMPLE, a trial of 646 patients comparing the subcutaneous formulation of Orencia, or abatacept, vs. Humira, or adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism annual congress and highlighted during a congress press conference. AMPLE met its primary endpoint as measured by non-inferiority of ACR20 at year one. The Orenica regimen achieved comparable rates of efficacy vs. the Humira regimen, or 64.8% vs. 63.4%, respectively. Onset of response was also generally similar for the two groups. Year two of the study remained investigator-blinded. At year two, the Orencia regimen achieved the same rate of efficacy as the Humira regimen based on ACR20. | | | 16:21 EDT |  | NVS | On The Fly: Closing Wrap
Stocks on Wall Street were lower after the Bank of Japan's decision to hold off on any further stimulus measures raised investor concern. The averages recovered much of their early losses in the morning, sitting just below the flat line near noon, but the selling intensified during the second half of the session, with the market trending lower into the close. ECONOMIC EVENTS: In the U.S., NFIB's small business optimism index rose to 94.4 in May from a prior 92.1 reading. Wholesale inventories rose 0.2% in April, matching expectations, and wholesale trade rose 0.5% from the prior month, versus expectations for a 0.1% slide. The Job Openings & Labor Turnover report for April showed openings fell 3% to a seasonally adjusted 3.75M, while hiring jumped nearly 5% to 4.4M. In Asia, the Bank of Japan refrained from changing its policies following recent volatility in its stock and bond markets. The dollar weakened considerably against the Yen, losing more than 2% to trade near the Y96 level. COMPANY NEWS: Sprint (S) shares jumped 17c, or 2.37%, to $7.35 after Japan's Softbank (SFTBF) increased its offer to acquire the telecom company in the face of a potential rival bid from DISH Network (DISH). MAJOR MOVERS: Among notable gainers was Questcor (QCOR), up $5.47, or 14.9%, to $42.18 after the company acquired the right to develop Synacthen from Novartis (NVS). Also higher was Catamaran (CTRX), up $5.33, or 10.95%, to $53.99 after the company struck a ten-year strategic pharmacy benefits agreement with Cigna (CI) and its stock received upgrades from at least three firms. Among noteworthy losers was lululemon (LULU), down $14.43, or 17.54%, to $67.85 after its CEO announced plans to step down and the stock was downgraded at Sterne Agee and UBS. Also lower was GenMark Diagnostics (GNMK) which lost $1.96, or 12.95%, to $13.17, after Natural Molecular Testing launched a cardiac testing panel using technology from GenMark's competitor Luminex (LMNX). INDICES: The Dow was down 116.57, or 0.76%, to 15,122.02; the Nasdaq was down 36.82, or 1.06%, to 3,436.95; and the S&P 500 was down 16.68, or 1.02%, to 1,626.13. | | | 16:07 EDT |  | NVS | PDL BioPharma sees Q2 royalty revenue $143M
Subscribe for More Information | | | 16:00 EDT | | PFE | Options Update; June 11, 2013
Subscribe for More Information | | | 15:15 EDT | | PFE | Pfizer June volatility at one-year high
Subscribe for More Information | | | | 12:32 EDT | | NVS | On The Fly: Midday Wrap
Stocks on Wall Street were lower at midday but well off their lows after the Bank of Japan held off from implementing any additional stimulus measures. The U.S. market followed Japan's benchmark stock index lower at the open, though the averages climbed back fairly steadily during the morning and stood near session highs just a bit below the flat line near noon. ECONOMIC EVENTS: In the U.S., NFIB's small business optimism index rose to 94.4 in May from a prior 92.1 reading. Wholesale inventories rose 0.2% in April, matching expectations, and wholesale trade rose 0.5% from the prior month, versus expectations for a 0.1% slide. The Job Openings & Labor Turnover report for April showed openings fell 3% to a seasonally adjusted 3.75M, while hiring jumped nearly 5% to 4.4M. In Asia, the Bank of Japan refrained from changing its policies following recent volatility in its stock and bond markets. The benchmark Nikkei fell about 1.5% as the decision disappointed investors who may have expected some action. COMPANY NEWS: Sprint (S) shares rose over 2% after Japan's Softbank (SFTBF) increased its offer to acquire the telecom company in the face of a potential rival bid from DISH Network (DISH). MAJOR MOVERS: Among the notable gainers was Catamaran (CTRX), which was upgraded by at least three Street firms and rose 11% after announcing a ten-year strategic pharmacy benefits deal with Cigna (CI). Also higher were shares of Questcor (QCOR), which jumped 19% after buying the rights to develop Synacthen from Novartis (NVS). Among the noteworthy losers was GenMark Diagnostics (GNMK), which fell 24% after Natural Molecular Testing launched a cardiac testing panel using technology from GenMark's competitor Luminex (LMNX). Also lower were shares of yoga apparel maker lululemon (LULU), which fell 17% after its CEO announced plans to step down and the stock was downgraded at Sterne Agee and UBS. INDICES: Near noon, the Dow was down 6.68, or 0.04%, to 15,231.91; the Nasdaq was down 11.21, or 0.32%, to 3,462.56; and the S&P 500 was down 4.89, or 0.30%, to 1,637.92. | | | 09:16 EDT | | NVS | On The Fly: Pre-market Movers
HIGHER: Dole Food (DOLE), up 21.9% after CEO offers buyout at $12 per share... Questcor (QCOR), up 32% after buying rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis (NVS), upgrade to Buy at CRT Capital... CardioNet (BEAT), up 44% after announcing a three-year national provider agreement with UnitedHealthcare Insurance (UNH)... Catamaran (CTRX), up 13.2% after announcing a ten-year strategic pharmacy benefits deal with Cigna (CI)... Sprint (S), up 2% after Softbank (SFTBF) increases buyout offer terms. Clearwire (CLWR) up 1.2%. LOWER: lululemon (LULU), down 14.9% after reporting earnings, CEO announces plans to step down, stock downgraded at Sterne Agee and UBS... Texas Instruments (TXN), down 2% after narrowing second quarter revenue, earnings forecast ranges... Corinthian Colleges (COCO), down 15.4% after disclosing the receipt of a subpoena from the SEC. Corinthian peer Career Education (CECO) 5.5%... Kinross Gold (KGC), down 5.5% after canceling development project in Ecuador, taking $720M charge, stock downgraded at Canaccord. DOWN AFTER EARNINGS: LDK Solar (LDK), down 8.5%. | | | 08:01 EDT | | BMY | Leerink's major pharma and biotech analysts hold a conference call
Subscribe for More Information | | | 07:42 EDT | | PFE | Boston Biotech Conferences to host a conference
Subscribe for More Information | | | 07:02 EDT | | NVS | Questcor acquires rights to develop Synacthen from Novartis
Subscribe for More Information | | | June 10, 2013 | | 07:40 EDT | | PFE | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information | | | 07:20 EDT | | PFE | Biomed to host a conference
Subscribe for More Information | | | June 7, 2013 | | 13:49 EDT | | BMY | Bristol-Myers volatility elevated as shares pullback from 11-year high
Subscribe for More Information | | | June 6, 2013 | | 11:04 EDT | | BMY | Bristol-Myers says Health Canada expands Abilify indications
Abilify has received an additional approval from Health Canada as an adjunct, or add-on, treatment to antidepressants for the treatment of major depressive disorder in adults who had an inadequate response to prior antidepressant treatments during the current episode. | |
|
|
|
|
|
|
